According to the latest SEC filings, insiders at Amicus Therapeutics, Inc. (NASDAQ:FOLD) have increased their position in the stock by 33.55% over the past 6 months. Insiders now own 0.90% of total outstanding shares.
University of Michigan professor and noted insider trading researcher discovered that when insiders bought shares of their own companies, the stocks outperformed the total market by 8.9% over the next 12-month period. When they sold shares, the stock underperformed 5.4%.
Amicus Therapeutics, Inc. (NASDAQ:FOLD) stands 26.96% away from its 50-day simple moving average and also 41.37% away from the 200-day average. Recently, the equity stands -2.61% away from the 52-week high and 124.04% from the 52-week low. The RSI (Relative Strength Index), an indicator that shows price strength by comparing upward and downward close-to-close movements is 76.10.
Wall Street analysts on the sell-side covering shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) have a mean recommendation of 1.50 on the shares. This is based on a numerical chart where each stock recommendation (Buy,Sell,Hold) is translated into a numerical equivalent. A low number indicates a Buy and a higher number a Sell. In terms of where analysts see the stock headed, they have a consensus price target of $12.92 on the shares.